Neuronal intermediate filament (IF) inclusion bodies are pathological protein aggregates composed of neuronal intermediate filament proteins that accumulate in various neurodegenerative diseases. These inclusions represent a hallmark of several proteinopathies affecting the nervous system and serve as important diagnostic markers and therapeutic targets[1][2].
Neuronal intermediate filaments are essential cytoskeletal components that maintain neuronal architecture, facilitate intracellular transport, and support proper axonal function. In neurodegenerative diseases, these proteins undergo pathological modifications including hyperphosphorylation, aggregation, and accumulation into inclusions that disrupt cellular function and contribute to neuronal death.
The neuronal intermediate filament family consists of several key proteins:
| Protein | Abbreviation | Molecular Weight | Primary Location |
|---|---|---|---|
| Neurofilament Light | NF-L | 61 kDa | All neurons |
| Neurofilament Medium | NF-M | 95 kDa | Large neurons |
| Neurofilament Heavy | NF-H | 200 kDa | Myelinated axons |
| α-Internexin | α-Int | 66 kDa | CNS neurons |
| Peripherin | PRPH | 57 kDa | PNS neurons |
These proteins assemble into heteropolymers that form the neuronal cytoskeleton, with NF-L serving as the backbone subunit that partners with NF-M and NF-H to create the characteristic neurofilament triplet[3].
Beyond the neurofilament triplet, several other intermediate filaments are relevant to neuronal biology:
Axonal spheroids are swellings that form along affected axons, containing accumulated neurofilament proteins[4]:
While primarily composed of α-synuclein, Lewy bodies also contain neurofilament components:
Although primarily composed of hyperphosphorylated tau, neurofibrillary tangles also contain neurofilament proteins:
In certain diseases, neurofilament proteins accumulate in perinuclear regions:
Neurofilament phosphorylation is a critical regulatory mechanism that becomes dysregulated in neurodegeneration[6][7][8]:
Multiple kinases contribute to neurofilament phosphorylation:
Glycogen Synthase Kinase-3β (GSK-3β)
Cyclin-Dependent Kinase 5 (CDK5)
Mitogen-Activated Protein Kinases (MAPKs)
Hyperphosphorylation leads to several detrimental effects:
The aggregation of neurofilament proteins involves several steps[9]:
Impaired protein quality control systems contribute to neurofilament accumulation[10][@ ubiquitin_nf]:
Emerging evidence suggests neurofilament pathology may spread in a prion-like manner[11]:
ALS shows prominent neurofilament pathology[12][13]:
Neurofilament abnormalities in AD include[14]:
PD shows characteristic neurofilament changes[5:1]:
Neurofilament pathology in HD[15]:
FTD spectrum disorders show:
Several therapeutic approaches target neurofilament pathology[16][17]:
Neurofilament proteins serve as valuable biomarkers[18][19]:
| Marker | Source | Disease Utility |
|---|---|---|
| NF-L | CSF, Blood | ALS, AD, PD, MS progression |
| NF-H | CSF, Blood | Axonal injury marker |
| pNF-H | CSF | ALS-specific marker |
| α-Internexin | CSF | FTD, AD |
Neuronal intermediate filament inclusion bodies represent a fundamental pathological feature across multiple neurodegenerative diseases. Understanding the mechanisms of neurofilament aggregation, phosphorylation, and propagation provides insights into disease pathogenesis and identifies potential therapeutic targets. The development of neurofilament-based biomarkers represents a significant advance in neurodegenerative disease diagnostics and clinical trial design.
Lee VM, et al. Neurofilament aggregates in neurodegenerative disease. Acta Neuropathol. 2019. ↩︎
Peled A, et al. Neurofilament light chain as biomarker in neurological disorders. Nat Rev Neurol. 2021. ↩︎
Nixon RA, et al. Neurofilament proteins: structure and function. Prog Brain Res. 1994. ↩︎
Corwin WL, et al. Axonal spheroids in neurodegenerative disease. Acta Neuropathol. 2017. ↩︎
Gertz K, et al. Neurofilament phosphorylation in Parkinson's disease. J Neurochem. 2002. ↩︎ ↩︎
Nixon RA, et al. Neurofilament phosphorylation and axonal transport. Biochem Soc Trans. 2007. ↩︎
Rudrabhatla P, et al. GSK-3beta-mediated phosphorylation of neurofilaments. Mol Cell Neurosci. 2010. ↩︎
Sharma M, et al. CDK5 phosphorylates neurofilament proteins. J Neurosci. 1999. ↩︎
Nixon RA, et al. Intermediate filament dysfunction in neurodegenerative diseases. Brain Pathol. 2005. ↩︎
Ravikumar B, et al. Autophagy and neurofilament degradation. Autophagy. 2008. ↩︎
Jucker M, et al. Propagation of protein aggregates in neurodegeneration. Trends Neurosci. 2013. ↩︎
Julius C, et al. Neurofilament pathology in ALS and FTD. Acta Neuropathol. 2021. ↩︎
Al-Chalabi A, et al. Neurofilament markers in ALS and ALS-FTD. Lancet Neurol. 2020. ↩︎
Zhukareva V, et al. Selective loss of neurofilament expression in Alzheimer's disease. Ann Neurol. 2002. ↩︎
Towell A, et al. Neurofilament abnormalities in Huntington's disease. Brain Res Bull. 2012. ↩︎
Bacioglu M, et al. Neurofilament-based therapeutic strategies. Brain. 2021. ↩︎
Brady S, et al. Targeting intermediate filaments in neurodegeneration. Neurotherapeutics. 2019. ↩︎
Khalil M, et al. Neurofilaments as biomarkers in neurological diseases. Nat Rev Neurol. 2018. ↩︎
Gisslén M, et al. Blood neurofilament light chain as biomarker in neurodegeneration. Nat Med. 2019. ↩︎